Kurse + Charts + RealtimeNews + AnalysenFundamentalUnternehmenzugeh. WertpapiereAktion
Kurs + ChartChart (groß)NewsBilanz/GuVDividende/HVZertifikateDepot/Watchlist
Times + SalesChart-AnalyseAnalysenSchätzungenTermineOptionsscheinemyHome
BörsenplätzeChartvergleichKursziele ProfilKnock-OutsSenden/Drucken
OrderbuchRealtime Stuttgart  InsidertradesFonds 
HistorischRealtime PushmyNews im ForumAnleihen
Kaufen
Verkaufen

27.02.2013 09:01

Senden

ARTIMPLANT YEAR-END-REPORT JANUARY – DECEMBER 2012

Artimplant AB (B) zu myNews hinzufügen Was ist das?


Regulatory News:

Artimplant AB (STO:ARTIB):

  • Net revenue increased by 15 percentage points and amounted to SEK 21.1 million (18.3).
  • The net loss after tax totaled SEK 16.5 million (17.9). This represented an improvement in result of SEK 1.4 million compared to the corresponding period the previous year.
  • Earnings per stock unit amounted to SEK -0.03 (-0.15).
  • The aim of achieving a positive cash flow before changes in working capital on a monthly basis was moved forward to the second half of 2013 due to low sales growth in the USA. The sales development is still weak and the impact of the litigations it is uncertain and therefore the Board can at present not determine when the cash flow will be positive.
  • The Board proposes that no dividend be paid for 2012.
  • The license agreement with Biomet Sportsmedicine was terminated in April.
  • The USA study of Artelon® Tissue Reinforcement for rotator cuff injuries has been published. The study shows positive results with regard to functioning of the shoulder and patients’ perceived improved quality of life.

Fourth quarter

  • Net revenue amounted to SEK 5.5 million (4.0) an improvement with 1.5 MSEK. European sales increased by 247 percentage points and the US sales by 25 percentage points compared to previous period.
  • The net loss after tax totaled SEK 6.4 million (6), a decreased by 0.4 MSEK compared to previous period due to higher legal costs in terms of increased legal costs caused by the ongoing insurance dispute.
  • Earnings per stock unit amounted to SEK -0.01 (-0.05).
  • Preliminary positive results presented from a two-year study of Artelon® CMC Spacer.

Events after the year-end

  • Artimplant prolongs its funding agreement regarding costs for trials in USA and recovers previous legal costs of SEK 5 million.
  • Artimplant has requested arbitration in the insurance dispute.
  • The Company is in need of a capital injection, the Board has therefore decided to review its strategic options

Further information is available at www.artimplant.com where you can also subscribe to future press releases; www.artimplant.com/investors-media/subscribe-to-press-releases.html

Artimplant

Artimplant is a biomaterials company focused on solutions to problems in orthopedics. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon®, meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet as well as shoulder and other soft tissue injuries.

Artimplant is a public company, listed on NASDAQ OMX Stockholm in the Small Cap segment and in the healthcare sector.

Forward-looking statements

This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting on the Company's business, including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

This is information that Artimplant will make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on February 27, 2013 at 8:55 am (Swedish time).

This information was brought to you by Cision http://news.cision.com

Kommentare zu diesem Artikel

Geben Sie jetzt einen Kommentar zu diesem Artikel ab.
Kommentar hinzufügen
  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • Sprache:
  • Alle
  • DE
  • EN
  • Sortieren:
  • Datum
  • meistgelesen
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen
Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen
vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden
Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Artimplant AB (B)

mehr
  • Alle
  • Buy
  • Hold
  • Sell
Keine Analysen gefunden.

AKTIEN IN DIESEM ARTIKEL

ANZEIGE

Private Krankenversicherung Tarifvergleich

Anzeige

Meistgelesene Artimplant AB (B) News 1M

Keine Nachrichten gefunden.
Weitere Artimplant AB (B) News

Artimplant AB (B) Peer Group News

Keine Nachrichten gefunden.

ANZEIGE

Die 5 beliebtesten Top-Rankings






Die Zahl der Beschwerden von Privatversicherten über ihre Krankenkasse ist 2013 leicht gesunken. Wie Zufrieden sind Sie mit Ihrer Krankenkasse?
Ich gehöre zu denen die sich beim Ombudsmann der privaten Krankenversicherung (PKV) beschwert haben.
Ich war im letzten Jahr unzufrieden, habe mich aber nicht beschwert.
Ich hatte keine Probleme mit meiner Versicherung
Abstimmen